NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status (Ascending) |
---|---|---|---|---|---|---|---|---|---|---|---|
60429-0265-01 | 60429-0265 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Oct. 26, 2012 | Dec. 31, 2024 | In Use |
60429-0433-01 | 60429-0433 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Sept. 4, 2015 | Dec. 31, 2024 | In Use | |
60429-0433-05 | 60429-0433 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Sept. 4, 2015 | March 31, 2024 | In Use | |
60505-6166-00 | 60505-6166 | clofarabine | Clofarabine | 1.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Jan. 1, 2018 | Jan. 31, 2025 | In Use |
60687-0112-11 | 60687-0112 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan. 15, 2016 | In Use | ||
60687-0112-21 | 60687-0112 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Feb. 3, 2016 | In Use | ||
60687-0286-11 | 60687-0286 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | July 7, 2017 | In Use | |
60687-0286-21 | 60687-0286 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | July 27, 2017 | Sept. 30, 2024 | In Use |
60687-0647-01 | 60687-0647 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 20, 2022 | Aug. 31, 2024 | In Use |
61703-0360-18 | 61703-0360 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 23, 2022 | In Use | |
61703-0360-22 | 61703-0360 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Oct. 14, 2004 | Oct. 31, 2015 | In Use |
61703-0360-50 | 61703-0360 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Dec. 25, 2009 | Jan. 31, 2016 | In Use |
60687-0718-01 | 60687-0718 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 17, 2022 | In Use | |
66993-0730-02 | 66993-0730 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 30, 2022 | In Use | |
66993-0730-80 | 66993-0730 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 3, 2023 | In Use | |
67457-0833-06 | 67457-0833 | Pegfilgrastim | Fulphila | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | July 9, 2018 | May 31, 2026 | In Use |
67457-0847-44 | 67457-0847 | Trastuzumab | OGIVRI | 420.0 mg/ 20 mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Nov. 29, 2019 | April 30, 2027 | In Use |
67457-0991-15 | 67457-0991 | Trastuzumab | OGIVRI | 150.0 mg/7.4mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Nov. 29, 2019 | Feb. 28, 2027 | In Use |
68001-0545-41 | 68001-0545 | Pemetrexed disodium | Pemetrexed | 750.0 mg/30mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 1, 2023 | In Use | |
68001-0546-41 | 68001-0546 | Pemetrexed disodium | Pemetrexed | 1000.0 mg/40mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 1, 2023 | In Use | |
68001-0557-00 | 68001-0557 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 31, 2023 | In Use | |
68001-0558-55 | 68001-0558 | Methylprednisolone | Methylprednisolone | 8.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 31, 2023 | In Use | |
68001-0559-69 | 68001-0559 | Methylprednisolone | Methylprednisolone | 16.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 31, 2023 | In Use | |
68001-0560-55 | 68001-0560 | Methylprednisolone | Methylprednisolone | 32.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 31, 2023 | In Use | |
68084-0220-01 | 68084-0220 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 1, 2023 | In Use |
Found 10,000 results in 9 milliseconds — Export these results